Physician profile
Thomas G Maher
NPI 1053332528
$1,311.49
in general payments reported to CMS, 2019-2025
12 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2021: $36.51 · 2022: $24.83 · 2023: $292 · 2024: $366 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $422.69 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $263.86 | 2019-2025 | Tryptyr |
| Abbvie INC. | $199.41 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $121.09 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $97.96 | 2023 | Iheezo |
| Oyster Point Pharma, INC. | $54.62 | 2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $37.22 | 2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.23 | 2019 | |
| Dompe US, INC. | $25.87 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $22.49 | 2025 | Miebo |
| Amgen INC. | $18.51 | 2024 | Tepezza |
| Coopervision INC. | $16.54 | 2023 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.